SynKIR-110 for Ovarian Cancer, Mesothelioma, or Cholangiocarcinoma
SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 1
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 42 (estimated)
- Sponsor
- Verismo Therapeutics · Industry
This trial is looking for adults with advanced ovarian cancer, mesothelioma, or cholangiocarcinoma who have had at least one previous treatment. Participants will receive a single intravenous dose of a treatment called SynKIR-110 to assess its safety and effectiveness.
You may be able to join if
- I have been diagnosed with ovarian cancer, mesothelioma, or cholangiocarcinoma.
- I am 18 years of age or older.
- I have a performance status score of 0 to 1.
- I have at least one measurable lesion.
- My blood coagulation parameters are satisfactory.
- My organ and bone marrow function are satisfactory.
You may not be able to join if
- I have active invasive cancers other than my diagnosed cancer.
- I have a history of T or B cell malignancies or previous gene-engineered T cell therapies.
- I have sarcomatoid or biphasic mesothelioma.
- I have any pulmonary issues.
- I have a known immunodeficiency disease.
- I have active hepatitis B, active hepatitis C, or any HIV infection.
- I have an active autoimmune disease.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your EligibilityThis first-in-human (FIH) trial is designed to assess the safety, feasibility, and potential activity of a single intravenous (IV) dose of SynKIR-110 administered to subjects with mesothelin-expressing advanced ovarian cancer, mesothelioma, and cholangiocarcinoma.
Loading trial locations…
No contact information available.